JP2003508439A5 - - Google Patents

Download PDF

Info

Publication number
JP2003508439A5
JP2003508439A5 JP2001519913A JP2001519913A JP2003508439A5 JP 2003508439 A5 JP2003508439 A5 JP 2003508439A5 JP 2001519913 A JP2001519913 A JP 2001519913A JP 2001519913 A JP2001519913 A JP 2001519913A JP 2003508439 A5 JP2003508439 A5 JP 2003508439A5
Authority
JP
Japan
Prior art keywords
buprenorphine
particulate composition
alcohol
effective dose
heroin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2001519913A
Other languages
English (en)
Japanese (ja)
Other versions
JP4913298B2 (ja
JP2003508439A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/023390 external-priority patent/WO2001015699A1/en
Publication of JP2003508439A publication Critical patent/JP2003508439A/ja
Publication of JP2003508439A5 publication Critical patent/JP2003508439A5/ja
Application granted granted Critical
Publication of JP4913298B2 publication Critical patent/JP4913298B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2001519913A 1999-08-27 2000-08-25 注射可能なブプレノルフィン微粒子組成物及びその使用 Expired - Lifetime JP4913298B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15111299P 1999-08-27 1999-08-27
US60/151,112 1999-08-27
PCT/US2000/023390 WO2001015699A1 (en) 1999-08-27 2000-08-25 Injectable buprenorphine microparticle compositions and their use

Publications (3)

Publication Number Publication Date
JP2003508439A JP2003508439A (ja) 2003-03-04
JP2003508439A5 true JP2003508439A5 (enExample) 2007-08-30
JP4913298B2 JP4913298B2 (ja) 2012-04-11

Family

ID=22537367

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001519913A Expired - Lifetime JP4913298B2 (ja) 1999-08-27 2000-08-25 注射可能なブプレノルフィン微粒子組成物及びその使用

Country Status (24)

Country Link
US (2) US6495155B1 (enExample)
EP (1) EP1212061B1 (enExample)
JP (1) JP4913298B2 (enExample)
KR (1) KR100730440B1 (enExample)
CN (2) CN100387228C (enExample)
AT (1) ATE280579T1 (enExample)
AU (1) AU765496C (enExample)
BR (1) BR0013650A (enExample)
CA (1) CA2382577C (enExample)
CY (1) CY1106043T1 (enExample)
CZ (1) CZ2002728A3 (enExample)
DE (1) DE60015370T2 (enExample)
EA (1) EA009080B1 (enExample)
ES (1) ES2230154T3 (enExample)
HK (1) HK1046858B (enExample)
HU (1) HUP0203613A3 (enExample)
IL (2) IL148343A0 (enExample)
MX (1) MXPA02002105A (enExample)
NO (2) NO322650B1 (enExample)
NZ (1) NZ517997A (enExample)
PL (1) PL198334B1 (enExample)
PT (1) PT1212061E (enExample)
RO (1) RO121631B1 (enExample)
WO (1) WO2001015699A1 (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL148343A0 (en) * 1999-08-27 2002-09-12 Southern Res Inst Injectable buprenorphine microparticle compositions and their use
US6495164B1 (en) * 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
ES2385030T3 (es) * 2001-06-29 2012-07-17 Medgraft Microtech, Inc. Implantes inyectables biodegradables y procedimientos relacionados con su fabricación y uso
AU2002303148A1 (en) * 2001-06-29 2003-03-03 Leon J. Lewandowski Individualized addiction cessation therapy
WO2003004030A1 (en) 2001-07-06 2003-01-16 Endo Pharmaceuticals, Inc. Oxymorphone controlled release formulations
US8329216B2 (en) 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
BR0205722A (pt) * 2001-07-06 2005-04-05 Penwest Pharmaceuticals Compan Formulação de liberação prolongada e método para o tratamento de um paciente que sofre de dor
AU2002337686B2 (en) * 2001-09-26 2008-05-15 Penwest Pharmaceuticals Company Opioid formulations having reduced potential for abuse
US7462366B2 (en) 2002-03-29 2008-12-09 Boston Scientific Scimed, Inc. Drug delivery particle
US7131997B2 (en) 2002-03-29 2006-11-07 Scimed Life Systems, Inc. Tissue treatment
US7094369B2 (en) 2002-03-29 2006-08-22 Scimed Life Systems, Inc. Processes for manufacturing polymeric microspheres
US7053134B2 (en) 2002-04-04 2006-05-30 Scimed Life Systems, Inc. Forming a chemically cross-linked particle of a desired shape and diameter
SI2561860T1 (en) 2002-05-31 2018-05-31 Titan Pharmaceuticals, Inc. An implantable polymeric device for prolonged release of buprenorphine
US7041320B1 (en) * 2002-05-31 2006-05-09 Biotek, Inc. High drug loaded injectable microparticle compositions and methods of treating opioid drug dependence
US7842377B2 (en) * 2003-08-08 2010-11-30 Boston Scientific Scimed, Inc. Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient
US7449236B2 (en) 2002-08-09 2008-11-11 Boston Scientific Scimed, Inc. Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient
US8012454B2 (en) 2002-08-30 2011-09-06 Boston Scientific Scimed, Inc. Embolization
US7883490B2 (en) 2002-10-23 2011-02-08 Boston Scientific Scimed, Inc. Mixing and delivery of therapeutic compositions
US7588825B2 (en) 2002-10-23 2009-09-15 Boston Scientific Scimed, Inc. Embolic compositions
WO2004078178A1 (en) * 2003-03-03 2004-09-16 Markus Heilig Buprenorphine compounds for treatment of alcohol dependence and excessive alcohol use
US20050031667A1 (en) 2003-03-31 2005-02-10 Patel Rajesh A. Implantable polymeric device for sustained release of dopamine agonist
US7976823B2 (en) 2003-08-29 2011-07-12 Boston Scientific Scimed, Inc. Ferromagnetic particles and methods
US7901770B2 (en) 2003-11-04 2011-03-08 Boston Scientific Scimed, Inc. Embolic compositions
US7736671B2 (en) 2004-03-02 2010-06-15 Boston Scientific Scimed, Inc. Embolization
US8173176B2 (en) 2004-03-30 2012-05-08 Boston Scientific Scimed, Inc. Embolization
US7919499B2 (en) 2004-04-22 2011-04-05 Alkermes, Inc. Naltrexone long acting formulations and methods of use
FR2869801B1 (fr) * 2004-05-05 2008-09-12 Ethypharm Sa Procede de preparation de compositions a liberation prolongee et utilisation de ces compositions pour le traitement des affections chroniques du systeme nerveux central (snc)
US7311861B2 (en) 2004-06-01 2007-12-25 Boston Scientific Scimed, Inc. Embolization
NZ582130A (en) 2004-08-04 2011-11-25 Clinuvel Pharmaceuticals Ltd Methods of inducing melanogenesis in a subject
US7727555B2 (en) 2005-03-02 2010-06-01 Boston Scientific Scimed, Inc. Particles
US7858183B2 (en) 2005-03-02 2010-12-28 Boston Scientific Scimed, Inc. Particles
US7963287B2 (en) 2005-04-28 2011-06-21 Boston Scientific Scimed, Inc. Tissue-treatment methods
US9463426B2 (en) 2005-06-24 2016-10-11 Boston Scientific Scimed, Inc. Methods and systems for coating particles
US20070141160A1 (en) * 2005-12-15 2007-06-21 Brown Laura J Method of treatment for osteoarthritis by local intra-articular injection of microparticles
US7501179B2 (en) 2005-12-21 2009-03-10 Boston Scientific Scimed, Inc. Block copolymer particles
US7947368B2 (en) 2005-12-21 2011-05-24 Boston Scientific Scimed, Inc. Block copolymer particles
WO2008106571A2 (en) * 2007-02-28 2008-09-04 Abbott Laboratories Sustained release parenteral formulations of buprenorphine
CA2699172C (en) * 2007-09-03 2016-05-17 Nanotherapeutics, Inc Compositions and methods for delivery of poorly soluble drugs
JP5502751B2 (ja) * 2007-12-20 2014-05-28 エボニック コーポレイション 低残留溶媒濃度を有する微粒子を調製するためのプロセス
CN104984343B (zh) * 2008-09-24 2019-04-02 赢创罗姆有限公司 耐受乙醇影响的非阿片类药物的pH依赖性受控释放的药物组合物
BRPI0823096B8 (pt) 2008-09-24 2022-07-05 Evonik Roehm Gmbh composição farmacêutica de opióide de liberação controlada, dependente do ph, com resistência contra a influência do etanol, processo para sua preparação, e seu uso
KR101535701B1 (ko) 2008-09-24 2015-07-09 에보니크 룀 게엠베하 에탄올의 영향에 대하여 내성을 갖는 비-오피오이드용 ph-의존성 조절 방출 제약 조성물
US20100268191A1 (en) * 2009-04-21 2010-10-21 Medtronic Vascular, Inc. Drug Delivery Catheter using Frangible Microcapsules and Delivery Method
US9125867B2 (en) 2010-02-24 2015-09-08 Invincible Biotechnology Diversion- and/or abuse-resistant compositions and methods for making the same
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
WO2013126552A1 (en) 2012-02-21 2013-08-29 Auburn University Buprenorphine nanoparticle composition and methods thereof
JP6279547B2 (ja) 2012-04-17 2018-02-14 パーデュー、ファーマ、リミテッド、パートナーシップ オピオイド誘発性有害薬力学的応答を治療するためのシステムおよび方法
CN102836131A (zh) * 2012-09-28 2012-12-26 山东大学 丁丙诺啡皮下注射用缓释微球制剂及其制备方法
US9636308B2 (en) 2013-03-15 2017-05-02 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same
US9393211B2 (en) * 2013-03-15 2016-07-19 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same
JP6135292B2 (ja) * 2013-05-10 2017-05-31 ニプロ株式会社 マイクロカプセル製剤の製造方法
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
WO2016071767A1 (en) 2014-11-07 2016-05-12 Indivior Uk Limited Buprenorphine dosing regimens
CN109069416A (zh) 2016-02-23 2018-12-21 拜欧帝力威瑞科学有限公司 缓释丁丙诺啡微球(srbm)及其使用方法
CA3033046C (en) 2016-09-13 2021-09-07 Alar Pharmaceuticals Inc. Sustained-release buprenorphine formulations
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
AR117426A1 (es) 2018-05-11 2021-08-04 Alar Pharmaceuticals Inc Formulaciones inyectables de acción prolongada y formas cristalinas de derivados de buprenorfina
US20220313686A1 (en) * 2019-08-12 2022-10-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Pharmaceutical compositions comprising a combination of opioid antagonists
US20210059943A1 (en) * 2019-09-04 2021-03-04 Buffalo Pacific LLC Systems and methods addressing multiple aspects to provide a comprehensive recovery program for addictions, chronic conditions and diseases

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464378A (en) 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4530840A (en) * 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US4568559A (en) 1984-02-06 1986-02-04 Biotek, Inc. Composite core coated microparticles and process of preparing same
US4623588A (en) 1984-02-06 1986-11-18 Biotek, Inc. Controlled release composite core coated microparticles
GB8430346D0 (en) * 1984-11-30 1985-01-09 Reckitt & Colmann Prod Ltd Analgesic compositions
US5143661A (en) * 1987-05-26 1992-09-01 American Cyanamid Company Silicone-hardened pharmaceutical microcapsules
FR2618674B1 (fr) 1987-07-30 1990-06-15 Ire Celltarg Sa Microparticules comportant un polymere biodegradable controlant la liberation d'un principe actif antimalarique, compositions pharmaceutiques en comprenant et procede de preparation
GB8728294D0 (en) 1987-12-03 1988-01-06 Reckitt & Colmann Prod Ltd Treatment compositions
US4902515A (en) * 1988-04-28 1990-02-20 E. I. Dupont De Nemours And Company Polylactide compositions
US5702716A (en) * 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
ATE133087T1 (de) 1989-05-04 1996-02-15 Southern Res Inst Einkapselungsverfahren
US5486362A (en) 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
AU2605592A (en) * 1991-10-15 1993-04-22 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5633000A (en) 1994-06-23 1997-05-27 Axxia Technologies Subcutaneous implant
US5716631A (en) 1995-09-29 1998-02-10 Rdn Therapeutics Inc. Long acting narcotic analgesics and antagonists
US5919473A (en) * 1997-05-12 1999-07-06 Elkhoury; George F. Methods and devices for delivering opioid analgesics to wounds via a subdermal implant
IL148343A0 (en) * 1999-08-27 2002-09-12 Southern Res Inst Injectable buprenorphine microparticle compositions and their use

Similar Documents

Publication Publication Date Title
JP2003508439A5 (enExample)
US11957785B2 (en) Film dosage form with extended release mucoadhesive particles
EP2805716B1 (en) A pharmaceutical composition comprising buprenorphine having a rapid action
JP7038741B2 (ja) 放出制御が容易な徐放性薬物微粒子の製造方法
EP2054029A1 (en) Subcutaneous implants releasing an active principle over an extended period of time
WO1994010982A1 (fr) Microsphere a liberation prolongee contenant un antipshychotique et procede de production
JP5038146B2 (ja) 誤用を避けるために設計された固形の経口的な剤形
TW522012B (en) Denaturants for sympathomimetic amine salts
BG65363B1 (bg) Фармацевтичен състав, съдържащ фентанил, за облекчаване на остра болка
WO2003013433A3 (en) Sequestered antagonist formulations
CH682715A5 (fr) Procédé de préparation de compositions à libération prolongée et compositions ainsi obtenues.
WO2003004024A1 (en) Injectable sustained-release microspheres of huperzine a compounds
CN101094653A (zh) 设计用于防止滥用的固体口服微粒剂型
JP2005132801A (ja) 口腔内崩壊錠
JP2001518923A (ja) 鼻腔用メラトニン組成物
CN101522169B (zh) 在延长的一段时间里释放活性成分的皮下植入剂
CN1674903A (zh) 经鼻吸收用组合物
JP2009539916A5 (enExample)
CA2544422A1 (en) Soft steroid compositions for use in dry powder inhalers
CN109069416A (zh) 缓释丁丙诺啡微球(srbm)及其使用方法
KR20100124860A (ko) 독소필린을 포함하는 변형 방출 조성물
US20240197717A1 (en) Sustained-release injectable composition containing naltrexone and method for preparing same
US20130116244A1 (en) Pharmaceutical powder compositions
JP2002541190A (ja) 気分障害治療用医薬を製造するためのオサネタントの使用
JP2003171264A (ja) マイクロカプセル及びその製造方法